Therapeutic Applications ·
The next generation of multi-agonist therapies may play a significant role in weight maintenance following bariatric surgery, particularly as researchers explore quad-agonist peptides that target multiple metabolic pathways.
The big picture
As the obesity epidemic continues to challenge healthcare systems worldwide, the development of innovative pharmacological strategies is critical. Following the promising results of existing therapies such as Tirzepatide and Retatrutide, the focus is shifting toward next-generation multi-agonist drugs. These therapies are designed to engage multiple hormonal pathways involved in appetite regulation and energy expenditure, potentially providing enhanced efficacy for weight maintenance post-bariatric surgery. While Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon, is currently in Phase 3 trials, the pipeline is also rich with candidates exploring quad-agonist and even penta-agonist configurations.
How it works
Multi-agonist therapies are predicated on the understanding that obesity is a multifactorial disease influenced by various hormones and metabolic pathways. By simultaneously activating multiple receptors, such as GLP-1, GIP, and glucagon, these drugs aim to create a synergistic effect that could lead to greater weight loss and improved metabolic health. Quad-agonists are hypothesized to combine the actions of existing dual agonists, like Mazdutide and Pemvidutide, with additional receptor targets to further enhance their therapeutic profile. The rationale is that engaging more pathways may improve appetite suppression, increase energy expenditure, and reduce the likelihood of weight regain after surgery.
Key points at a glance
- Retatrutide is a triple agonist in Phase 3 trials, targeting GLP-1, GIP, and glucagon.
- Quad-agonist therapies are being explored to enhance metabolic outcomes post-bariatric surgery.
- Multi-agonist drugs aim to engage multiple hormonal pathways to improve efficacy.
- Current approved therapies include Tirzepatide (dual GLP-1/GIP) and Semaglutide (GLP-1 mono-agonist).
- Research is ongoing for various candidates, including quad and penta-agonists in early clinical stages.
- Potential candidates may include combinations of existing dual agonists and novel receptor targets.
- Studies suggest that multi-agonist approaches could mitigate weight regain after bariatric surgery.
Where this fits in the pipeline
While no quad-agonist or penta-agonist drugs are currently approved, several candidates are in early clinical stages. For instance, HM15275 from Hanmi is a quad-agonist under investigation, while other programs are in preclinical development. The landscape is evolving, with companies like Amgen and Novo Nordisk also exploring multi-agonist strategies. Publicly disclosed data on these candidates is limited, but early-stage trials may provide insights into their potential benefits and risks.
What it could mean for patients
If successful, quad-agonist therapies could significantly improve weight maintenance for patients post-bariatric surgery. By targeting multiple pathways involved in appetite and metabolism, these drugs may offer a more comprehensive approach to managing obesity. However, it is essential to approach these developments cautiously, as the long-term safety and efficacy of these multi-agonist therapies remain to be fully established.
Open questions and what we don't yet know
Despite the promising potential of quad-agonists, several uncertainties remain. Key questions include the optimal receptor combinations for efficacy, the safety profiles of these new therapies, and their long-term effects on weight management and metabolic health. Additionally, regulatory pathways for these complex molecules are still being defined, which may influence their development timelines and market availability.
Bottom line
The exploration of quad-agonist therapies represents a forward-looking approach in the management of obesity, particularly for patients seeking to maintain weight loss after bariatric surgery. The field is evolving, but much remains to be understood.
This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.